Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aligos Therapeutics, Inc. - Common stock (NQ: ALGS )

23.67 +2.66 (+12.66%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aligos Therapeutics, Inc. - Common stock

< Previous 1 2 3 4 5 6 Next >
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Aligos Therapeutics to Announce 3rd Quarter Results on November 2, 2023
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics To Present Late Breaking Poster on ALG-000184, its CAM-E Drug Candidate, at The Liver Meeting® 2023
From Aligos Therapeutics
Via GlobeNewswire
Why Aligos Therapeutics (ALGS) Stock Is Nosediving
Aligos Therapeutics Inc (NASDAQ: ALGS) shares are trading lower by 15.8% to $0.64 Monday afternoon after the company announced $92 million in private placement financing 
Via Benzinga
Recap: Aligos Therapeutics Q1 Earnings
Via Benzinga
Aligos Therapeutics Earnings Preview
Via Benzinga
Aligos Therapeutics Earnings Perspective: Return On Capital Employed
Via Benzinga
A Preview Of Aligos Therapeutics's Earnings
Via Benzinga
Aligos Therapeutics Announces $92 Million Private Placement Financing
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Announces Award of an $8.5 Million NIAID Contract to Advance Development of Best-In-Class Pan-Coronavirus Protease Inhibitor, ALG-097558
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Announces IND Clearance for NASH lead, ALG-055009
- Phase 2a NASH protocol on track to be submitted to the IND in Q4 2023, enrollment expected to begin in Q1 2024 
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2023 Financial Results
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics to Announce Second Quarter Results on August 03, 2023
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Announces the Selection of Stephen Harrison, MD as Principal Investigator of Ph2a Study and Key Study Design Elements/Milestones for NASH Drug Candidate, ALG-055009
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Presents Data from its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics to Present Data on its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics to Present at the Jefferies 2023 Healthcare Conference
From Aligos Therapeutics
Via GlobeNewswire
Week In Review: LaNova Sells Pre-Clinical ADC To AstraZeneca In $600 Million Deal
LaNova Medicines has sold global rights for a pre-clinical antibody drug conjugate candidate to AstraZeneca for $600 million, including $55 million upfront plus royalties on sales. Meanwhile, Amoytop... 
Via Talk Markets
Why Venus Concept Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers NeoGames S.A. (NASDAQ: NGMS) shares climbed 113.3% to $27.38 as the company agreed to be acquired by Aristocrat Leisure Limited for $29.50 per share in cash. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why NeoGames Shares Are Trading Higher By 121%; Here Are 20 Stocks Moving Premarket
Gainers NeoGames S.A. (NASDAQ: NGMS) shares surged 121% to $28.38 in pre-market trading as the company agreed to be acquired by Aristocrat Leisure Limited for $29.50 per share in cash. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
We're starting off the week with a breakdown of the biggest pre-market stock movers worth keeping an eye on Monday morning! 
Via InvestorPlace
Aligos Therapeutics Announces Research Collaboration and Development Agreement with Xiamen Amoytop Biotech Co. Ltd. for Use of Aligos’ Oligonucleotide Platform for the Treatment of Liver Diseases
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2023 Financial Results
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics to Announce First Quarter Results on May 4, 2023
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics to Present Data from Chronic Hepatitis B and Hepatocellular Carcinoma Programs at the European Association for the Study of the Liver (EASL) Congress 2023
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Presents Clinical Data from NASH Program at the 2023 Paris Hepatology Conference
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2022 Financial Results
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics to Announce Fourth Quarter Results March 9, 2023
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Presents Program Updates at the 32nd Conference of the Asian Pacific Association for the Study of the Liver
From Aligos Therapeutics
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.